Table 2.
Characteristics and outcomes according to recipient quantitative anti-CMV IgG value.
| CMV seropositive recipients | Group A: anti-CMV IgG ≥250 AU/ml | Group B: anti-CMV IgG 6–249 AU/ml | Group C: anti-CMV IgG 0–5 AU/ml | p value | Post-hoc p value A/B | Post-hoc p value A/C | Post-hoc p value B/C |
|---|---|---|---|---|---|---|---|
| n (%) | 58 (13.18) | 208 (47.27) | 174 (39.55) | – | – | – | – |
| Age in years ± SD | 53.8 ± 12.8 | 50.5 ± 14.2 | 46.7 ± 13.5 | 0.001 | 0.122 | 0.001 | 0.007 |
| Female, n (%) | 27 (46.55) | 93 (44.71) | 65 (37.36) | 0.264 | |||
| Donor CMV seropositive, n (%) | 36 (62.07) | 136 (65.38) | 41 (23.56) | <0.001 | 0.755 | <0.001 | <0.001 |
| Conditioning, n (%) | 0.993 | – | – | – | |||
| MAC | 11 (18.97) | 41 (19.71) | 34 (19.54) | ||||
| NMA | 3 (5.17) | 8 (3.85) | 8 (4.60) | ||||
| RIC | 44 (75.86) | 159 (76.44) | 132 (75.86) | ||||
| Disease risk, n (%) | – | – | – | ||||
| Low | 11 (19.30) | 31 (15.12) | 20 (11.49) | ||||
| Intermediate | 22 (38.60) | 105 (51.22) | 84 (48.28) | 0.149 | |||
| High | 21 (36.84) | 48 (23.41) | 57 (32.76) | ||||
| Very high | 3 (5.26) | 21 (10.24) | 13 (7.47) | ||||
| Optimal match vs. mismatch, n (%) | 41 (70.69) | 156 (75.00) | 135 (77.59) | 0.560 | – | – | – |
| CMV infection event, n (%) | <0.001 | 0.036 | <0.001 | <0.001 | |||
| No infection | 5 (8.62) | 47 (22.60) | 160 (91.95) | ||||
| subCMVi | 14 (24.14) | 54 (25.96) | 6 (3.45) | ||||
| csCMVi | 39 (67.24) | 107 (51.44) | 8 (4.60) | ||||
| CMV peak viral load in IU/ml (IQR) | 3840.0 (1370.0–10900.0) | 3440.0 (1190.0–9870.0) | 1795.0 (364.8–7390.0) | 0.551 | – | – | – |
| Days of CMV reactivation (IQR) | 78.5 (33.2–147.0) | 88.0 (38.0–161.0) | 12.5 (7.0–119.8) | 0.018 | 0.400 | 0.042 | 0.017 |
| Days between TX and CMV reactivation (IQR) | 39.0 (25.0–52.5) | 30.5 (24.0–42.0) | 47.0 (37.0–116.0) | 0.031 | 0.150 | 0.195 | 0.072 |
| Death, n (%) | 43 (74.14) | 98 (47.34) | 93 (53.76) | 0.001 | 0.002 | 0.015 | 0.253 |
MAC myeloablative conditioning, NMA non-myeloablative, RIC reduced intensityconditioning, subCMVi subclinical infection, csCMVi clinically significantinfection, IQR interquartile range.